(Q34519212)

2 August 2017

1 reference

title

Antifungal use in HIV infection (English)

1 reference

2 August 2017

Francisco Marty

1

0 references

author name string

Eleftherios Mylonakis

series ordinal

2

1 reference

2 August 2017

language of work or name

English

0 references

publication date

1 February 2002

1 reference

Expert Opinion on Pharmacotherapy

2 August 2017

published in

1 reference

2 August 2017

volume

3

1 reference

2 August 2017

issue

2

1 reference

2 August 2017

page(s)

91-102

1 reference

Recurrent blastomycosis of the central nervous system: case report and review

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.2.91

Therapeutic efficacy of a liposomal formulation of amphotericin B (AmBisome) against murine blastomycosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.2.91

In vitro activities of voriconazole, itraconazole, and amphotericin B against Blastomyces dermatitidis, Coccidioides immitis, and Histoplasma capsulatum

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.2.91

Treatment of blastomycosis with higher doses of fluconazole. The National Institute of Allergy and Infectious Diseases Mycoses Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.2.91

A systematic review of the effectiveness of antifungal drugs for the prevention and treatment of oropharyngeal candidiasis in HIV-positive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.2.91

A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.2.91

A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.2.91

Coccidioidomycosis during human immunodeficiency virus infection: results of a prospective study in a coccidioidal endemic area

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.2.91

Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.2.91

Clinical utility of monitoring serum cryptococcal antigen (sCRAG) titers in patients with AIDS-related cryptococcal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.2.91

Discontinuation of secondary prophylaxis for cryptococcal meningitis in HIV-infected patients responding to highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.2.91

Correlation of fluconazole MICs with clinical outcome in cryptococcal infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.2.91

In-vitro susceptibility of Cryptococcus neoformans isolates to fluconazole and itraconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.2.91

Treatment of hydrocephalus secondary to cryptococcal meningitis by use of shunting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.2.91

Emergence of resistance to fluconazole as a cause of failure during treatment of histoplasmosis in patients with acquired immunodeficiency disease syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.2.91

Endemic mycoses: a treatment update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.2.91

A controlled trial of itraconazole to prevent relapse of Penicillium marneffei infection in patients infected with the human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.2.91

Penicillium marneffei: types and drug susceptibility.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.2.91

A controlled trial of itraconazole as primary prophylaxis for systemic fungal infections in patients with advanced human immunodeficiency virus infection in Thailand

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.2.91

21 January 2018

Identifiers

DOI

10.1517/14656566.3.2.91

1 reference

2 August 2017

1 reference